Search Results
Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
ASH 2014: Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
Phase III ASPIRE study and prospective anti-CD38 therapy for myeloma
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
Phase III study shows carfilzomib is an effective addition to standard myeloma therapy
Results of the ASPIRE trial for MM: the addition of carfilzomib
Dr. Keith Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial
Myeloma Expert Brian Durie Discusses the ASPIRE Trial
ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy
Updates from ASPIRE and ENDEAVOR
ENDEAVOUR, ASPIRE and TOURMALINE-MM1 trial results for multiple myeloma
